StockIQpro
NASDAQ:KPTI

Karyopharm Therapeutics Inc.

Track all markets on TradingView
Track all markets on TradingView

Karyopharm Therapeutics Inc.'s revenue grew 0.6% in fiscal 2025 to $146.1M while operating margin rose to −62.1%. Free cash flow was −$75.4M, −51.6% of revenue, and the diluted share count rose 29.3%.Summary generated from Karyopharm Therapeutics Inc.'s SEC filings. Latest annual report filed Feb 13, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$146.1M
Revenue growth+0.6%
Revenue, 5-yr CAGR+6.2%
Gross marginn/a
Operating margin−62.1%
Net margin−134.2%
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flow−$75.4M
FCF margin−51.6%
Share count change+29.3%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue210157146145146
Operating income−98−142−130−119−91
Net income−124−165−143−76−196
Free cash flow−107−150−93−128−75

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations